3 years ago

Long-term follow-up of half-fluence photodynamic therapy in acute central serous chorioretinopathy

Eva Smretschnig, Stefan Hagen, Jutta Gamper, Ilse Krebs, Susanne Binder, Siamak Ansari-Shahrezaei

Summary

Background

To evaluate the long-term results of indocyanine green angiography(ICGA)-guided verteporfin (Visudyne®, Novartis, Basel, Switzerland) photodynamic therapy (PDT) with half-fluence rate in the treatment of acute symptomatic central serous chorioretinopathy (CSC).

Material and methods

A retrospective review was performed of 12 patients with acute symptomatic CSC verified by spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography (FA), treated with ICGA-guided verteporfin (6 mg/m2)-PDT with half-fluence rate (25 J/cm2). The vision-related quality of life (VR QOL) 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25) was completed by all patients and 82 controls.

Results

Best corrected visual acuity (BCVA) at baseline was 77.5 (±10; n = 12) according to the Early Treatment Diabetic Retinopathy Study (EDTRS) letter score and changed to 89 letters (±9.9; p = 0.0003) at long-term follow-up (83.8 ± 4.8 months after PDT). Baseline contrast sensitivity (CS) was 29.5 ± 4.5 Pelli–Robson letters and increased to 34.5 ± 4.5 letters at long term (p < 0.0006). Baseline central foveal thickness (CFT) was 419 μm and decreased to 242 µm at long term (p < 0.0001). The long-term vision-related quality of life of patients was similar to that of controls.

Conclusion

ICGA-guided half-fluence PDT with verteporfin results in excellent long-term visual improvement in BCVA and CS, a significant reduction of CFT, and high levels of VR QOL.

Publisher URL: https://link.springer.com/article/10.1007/s00717-018-0412-y

DOI: 10.1007/s00717-018-0412-y

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.